|
|||||
|
|
AGAP2-AS1 serves as an oncogenic lncRNA and prognostic biomarker in glioblastoma multiforme |
|
| Authors: | Yanlong Tian Yong Zheng Xin Dong |
| Institution: | 1. Department of Pathology, No. 215 Hospital of Shaanxi Nuclear Industry, Xianyang, Shaanxi, China
Yanlong Tian and Yong Zheng contributed equally to this study.;2. Department of Neurosurgery, Shenzhen Baoan People's Hospital, Shenzhen, Guangdong, China Yanlong Tian and Yong Zheng contributed equally to this study.;3. Department of Neurosurgery, Xianyang Hospital of Yan’an University, Xianyang, Shaanxi, China |
| Abstract: | Long noncoding RNA (lncRNA) AGAP2 antisense RNA 1 (AGAP2-AS1) has been suggested to function as an oncogenic lncRNA in lung cancer, breast cancer, and anaplastic glioma. However, the expression pattern and molecular mechanism of AGAP2-AS1 in glioblastoma multiforme (GBM) remains unknown. The purpose of this study is to present more evidence about the clinical and biological function of AGAP2-AS1 in GBM. In our results, we found AGAP2-AS1 expression was increased in GBM compared with adjacent normal brain tissues or low-grade glioma tissues, and there was no significantly different between low-grade glioma tissues and normal tissues. Kaplan-Meier survival analysis indicated patients with GBM having high-expression of AGAP2-AS1 had shorter overall survival time than those with low expression of AGAP2-AS1. The loss-of-function studies showed that downregulation of AGAP2-AS1 depressed cell proliferation, migration, and invasion, and promoted cell apoptosis in GBM. In summary, AGAP2-AS1 is a prognostic biomarker for patients with GBM, and functions as an oncogenic lncRNA to modulate GBM cell proliferation, apoptosis, migration, and invasion, which suggests that AGAP2-AS1 is potential therapeutic target for GBM. |
| Keywords: | AGAP2-AS1 GBM glioblastoma multiforme glioma lncRNA |